Adherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA
|
|
- Clement Barker
- 6 years ago
- Views:
Transcription
1 Adherence to therapy Kamlesh Khunti University of Leicester, UK William Polonsky University of California San Diego, USA 1
2 Dualities of interest Kamlesh Khunti: Honoraria for speaking, advising or research from AstraZeneca Pharmaceuticals LP, Bristol- Myers Squibb Company, Eli Lilly and Company, Janssen, Merck Sharp & Dohme Corporation, Novartis Pharmaceuticals Corporation, Novo Nordisk, Boehringer Ingelheim, Roche and Sanofi William Polonsky: Honoraria for speaking, advising or research from Sanofi, Novo Nordisk, Lilly, Dexcom, Abbott Diabetes Care, Roche Diagnostics, Bayer Diabetes Care, Amylin and GlaxoSmithKline. GLB-DIA
3 Objectives of this workshop Discuss the definition of adherence Discuss the following questions: How do you ask/assess medication adherence in your patients? What do you feel are the key reasons for medication non-adherence in your patients? What effective strategies have you discovered for addressing poor medication adherence? 3
4 Components of adherence and established measures Adherence has two separate components Compliance is the degree to which a patient correctly follows medical advice For example, administering the right number of injections each day Persistence is a measure of the duration for which the patient remains compliant Common measures of adherence include: Medication possession ratio (MPR) Calculated using prescription-claims data Total number of days that prescriptions are supplied for in the analysis period divided by the total number of days in the analysis period Proportion of days covered Number of days during the analysis period for which the patient is covered (i.e. has access to medication) divided by the total number of days in the analysis period] Many studies use self-administered questionnaires to obtain measures of adherence; the methodology of these questionnaires can vary enormously Davies MJ, et al. Diabet Med 2013;30:
5 The adherence problem MPR < 80% is considered as poorly adherent Kaiser Permanente, T2DM n = 9377: 30% poorly adherent to >1 cardiometabolic medication VHA National Database, T2DM n = 740,195: 42% poorly adherent to >1 hypoglycemic agent 5
6 Poor adherence is common and associated with adverse outcomes 21% patients with diabetes were poorly adherent Poor adherence was associated with lower target achievement and increased hospitalization and mortality Adherent patients Non-adherent patients P value All-cause mortality, % <0.001 All-cause hospitalizations, % <0.001 Mean (SD) HbA 1C, % 7.7 (1.5) 8.1 (1.9) <0.001 Mean systolic BP, mmhg Mean diastolic BP, mmhg <0.001 Mean LDL-C, mg/dl <0.001 Retrospective cohort study 11,532 patients with diabetes in a managed care organization Ho PM et al. Arch Intern Med. 2006;166:
7 Poor adherence is associated with poor glycemic control In a Japanese study, 29% reported less than optimal adherence Good good glycemic control (HbA 1C <7%) was associated with fewer missed injections Never missed insulin injections Seldom missed insulin injections Missed insulin injections less than half of the time to always P value HbA 1C, % <0.001 Adjusted RRs for good glycemic control (95% CI) ( ) 0.64 ( ) DDCRT 3 1,441 patients with T2DM who were treated with insulin in a diabetes registry in Japan DDCRT 3, Diabetes Distress and Care Registry at Tenri Mashitani T et al. Diabetes Res Clin Pract. 2013;100:
8 Poor adherence is associated with increased costs Poor medication adherence in diabetes was associated with 37% lower pharmacy costs and 7% lower outpatient costs, but 41% higher inpatient costs Improving adherence would result in annual estimated cost savings of $661 million to $1.16 billion Inpatient cost, $1,000 Analysis of US Veterans with T2DM N=740,165 Followed from 2002 to 2006 or until lost to follow up Adherence, medication possession ratio 0.8 Non-adherence, medication possession ratio < Fiscal year Egede LE, et al. Diabetes Care 2012;35:
9 Among YOUR diabetes patients, how common is poor medication adherence? A Less than 10% of my patients B C D E F 11 20% 21 30% 31 40% 41 50% More than half of my patients 9
10 How do you ask/assess medication adherence in your patients?
11 What do you feel are the key reasons for medication non-adherence in your patients?
12 Medication obstacles Forgetfulness Depression Treatment complexity Medication costs Patient-provider trust Beliefs about diabetes and medications 12
13 Depression and medication use Comparing depressed vs non-depressed patients with diabetes: More likely to omit insulin Twice as likely to be skipping OHAs Depressed patients evidence 20% fewer days of adequate OHA medication coverage More likely to be skipping antihypertensive and lipid-lowering medicines Polonsky WH, et al. Diabetes Spectrum. 2000;13: (C) Ciechanowski PS, et al. Arch Intern Med. 2000;160: (B) Kilbourne AM, et al. Am J Geriatr Psychiatry. 2005;13: (B) Kalsekar ID, et al. Ann Pharmacother. 2006;40: (B) Lin EH, et al. Diabetes Care. 2004;27: (B) 13
14 % of Days Medication Taken Properly Treatment complexity Once Twice Thrice Paes AH, et al. Diabetes Care. 1997;20: (B) 14
15 Physician-patient relationship Relationship Between Consultation Attributes and Compliance With Medications (the Dependent Variable) in logistic Regression Analysis (N=172) Consultation variable Unadjusted OR (95% CI) Adjusted* OR (95% CI) Trust in physician scale score 1.07 ( ) 1.04 ( ) Continuity of care UPC index 0.90 ( ) 0.99 ( ) Usual source of care 2.87 ( ) 5.98 ( ) Length of care with same doctor 0.94 ( ) 0.86 ( ) Importance of seeing same doctor each visit 0.86 ( ) 0.80 ( ) Enablement index 1.03 ( ) 1.05 ( ) Physician-patient concordance score 1.21 ( ) 1.34 ( ) Kerse et al,
16 What does trust mean? To what extent do you think the doctor understands why you came in today? How well do you think the doctor understood you today? To what extent did you and the doctor agree about the main problem or need today? To what extent did you and the doctor agree about what to do about the problem or need?
17 Patients medication beliefs Adherence is better when medication is perceived as worth the effort Dosage must be sufficient Patients must know why they are taking their medications, and how to take them Perceived gain must outweigh perceived cost including side-effects 17
18 Among YOUR patients, what is the main contributor to poor insulin adherence? A Forgetfulness B C D E F G Depression Treatment complexity Medication costs Patient-provider trust Beliefs about diabetes and medications Something else! 18
19 What effective strategies have you discovered for addressing poor medication adherence?
20 Predictive factors for adherence to insulin and strategies for improving adherence to insulin Positive predictors of adherence to insulin Changing insulin therapy Switching from a vial/syringe to a pen device Initiating insulin therapy with a pen device instead of a vial/syringe Changing type of insurance plan Switching from a traditional formulary scheme to a value-based insurance design Predictive factors for adherence to insulin Negative predictors of adherence to insulin Switching from a vial/syringe to a pen device Strategies for improving adherence Increased use/availability of pen devices Reduce the financial burden of insulin therpy to the patient Older age Support from a diabetic nurse specialist Physical disability Higher household income Following a healthy diet Perceived self-efficacy Hypoglycemia awareness Previous experience of liaison psychiatry Previous experience of cognitive behavioural therapy Patient-perceived barriers to insulin adherence Lower perceived consequences of diabetes Higher perception of personal control Older age Female gender Single status Lower HbA 1c levels Being a student Having the highest level of education Needing a large number of injections Type 2 diabetes (vs. type 1) Provide additional medical support to patients (e.g. nurses, psychiatrists) Educational programmes to increase awareness of diabetes Develop therapies that allow for fewer injections and increased flexibility in treatment regimen Provide additional medical support to patients (e.g. nurses, psychiatrists) Davies MJ, et al. Diabet Med 2013;30:
21 A1C Anchoring medication to daily events 8.00 Anchors Does not anchor A daily event (a meal, TV show, bedtime, brushing my teeth) reminds me. Littenberg B, et al. BMC Fam Prac. 2006;7:1. (B) 21
22 Meta-analysis of RCTs to improve medication adherence 69 RCT s, multiple chronic illness conditions Most intervention have been shown to enhance adherence, but: Even the most effective interventions did not lead to large improvements in adherence and treatment outcomes. Haynes et al, Cochrane Database Syst Rev Apr 16;(2):CD000011
23 Change in HbA 1c (%) Educational interventions to overcome hypoglycaemia 0.4 Baseline 6 months 12 months 18 months Overall effect: 0.48 ( 0.76 to 0.21), p=0.001 Intervention Control Crasto W et al. Diabet Res Clin Pract 2011;93:
24 Hypoglycaemic events Events Intensive group Control group P value Hypoglycaemic event, n(%) Grade 1 (mild) 39 (42.4) 31 (32.5) 0.52 Grade 2 (moderate) 11 (11.2) 27 (29) < 0.05 Grade 3 (severe) 0 6 (6.3) 0.06 Crasto et al. Diabet Res Clin Pract 2011;93(3):328-36
25 Four medication secrets 1. Taking your medications is one of the most powerful things you can do to positively affect your health 2. Your medications are working even if you can t feel it 3. Needing more medication isn t your fault 4. More medication doesn t mean you are sicker, less medication doesn t mean you are healthier 25
26 26
Patient Engagement: The Dilemma of Poor Adherence to Blood Pressure Medications
Patient Engagement: The Dilemma of Poor Adherence to Blood Pressure Medications William H. Polonsky, PhD, CDE May 15, 2014 whp@behavioraldiabetes.org Mr. Reynolds Age 59, divorced, self-employed CPA T2D
More informationUnderstanding and Addressing Problematic Medication Adherence
Understanding and Addressing Problematic Medication Adherence William H. Polonsky PhD, CDE November 10, 2017 whp@behavioraldiabetes.org RATES OF VERY POOR GLYCEMIC CONTROL HEDIS data from >1000 health
More informationPresenter Disclosure
Presenter Disclosure Linong Ji.M.D Consulting and lecture fee Eli Lilly, Bristol-Myers Squibb, Novartis, Novo Nordisk, Merck, Bayer, Takeda, Sanofi-Aventis, GlaxoSmithKline, Roche, Johnson & Johnson, boehinger
More informationEfficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes
https://helda.helsinki.fi Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Riddle, Matthew C. 2016-04-01 Riddle, M C, Bolli, G B,
More informationBRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH
Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,
More informationInsights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
More informationCase study: Individual with inadequate glycaemic control due to poor adherence to medication
Case study: Individual with inadequate glycaemic control due to poor adherence to medication Authored by Linong Ji and Clifford Bailey on behalf of the Global Partnership for Effective Diabetes Management.
More informationTarget Audience. approach this patient case scenario, including identifying an
Activity Overview In this case-based webcast, meet LaWanda, a 57-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 8.4%, she is currently taking basal insulin and fast-acting insulin,
More informationThe Practice of Delivering Diabetes Medicines Optimisation. Elizabeth Hackett Principal Pharmacist for Diabetes
The Practice of Delivering Diabetes Medicines Optimisation Elizabeth Hackett Principal Pharmacist for Diabetes University i Hospitals Leicester Agenda Background (NaDIA and local data) Challenges facing
More informationThe Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections
8/5/217 The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections Richard M. Bergenstal, MD Executive Director International Diabetes Center at Park Nicollet Minneapolis,
More informationEngaging the Disengaged: Strategies for Promoting Behavior Change in Diabetes. William H. Polonsky, PhD, CDE
Engaging the Disengaged: Strategies for Promoting Behavior Change in Diabetes William H. Polonsky, PhD, CDE whp@behavioraldiabetes.org 1 % reaching ADA target Percentage of Patients Achieving ADA Treatment
More informationRole of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD
Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD International Diabetes Center and Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationThe GUIDANCE study. Kamlesh Khunti University of Leicester, UK. on behalf of the GUIDANCE Study Group
The GUIDANCE study Guillaume Charpentier, Kris Doggen, Noëmi Debacker, Kees Gorter, Odile Juy Christiane Kellner, Kamlesh Khunti, Oliver Kuß, Ulf Lindblad, Arne Melander, Lena Minning, Ulrich Müller, John
More informationTransforming Diabetes Care
Transforming Diabetes Care Barriers to Mealtime Insulin Dosing Mark Peyrot, PhD Loyola University Maryland, Baltimore, MD Faculty Background Principle Investigator DAWN and DAWN2 studies (Novo Nordisk)
More informationDiabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust
Diabetes Update: Keeping patients safe Victoria Ruszala MFRPSII North Bristol NHS Trust Declaration of Interests I have received funding from the following companies for providing education sessions, attending
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationEngaging the Disengaged:
Engaging the Disengaged: Strategies for Promoting Behavior Change in Diabetes William H. Polonsky, PhD, CDE November 6, 2016 whp@behavioraldiabetes.org Percentage of Patients Achieving ADA Treatment Targets
More informationSESSION 1: BASAL INSULINS: STILL INNOVATING AFTER ALL THESE YEARS
SESSION 1: BASAL INSULINS: STILL INNOVATING AFTER ALL THESE YEARS This Sanofi sponsored symposium, titled Evolving Standards and Innovation in Diabetes Care, took place on th September 201, as part of
More informationInsulin Pumps and Glucose Sensors in Diabetes Management
Diabetes Update+ 2014 Congress Whistler, British Columbia Friday March 21, 2014ǀ 8:15 8:45 am Insulin Pumps and Glucose Sensors in Diabetes Management Bruce A Perkins MD MPH Division of Endocrinology Associate
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationNEWS BRIEFING Adjunctive Therapies in Type 1 and Type 2 Diabetes
NEWS BRIEFING Adjunctive Therapies in Type 1 and Type 2 Diabetes Moderated by: Bernard Zinman, MD, CM, FRCPC, FACP Lunenfeld-Tanenbaum Research Institute and University of Toronto Mount Sinai Hospital
More informationFactors Affecting Use of Insulin Pens by Patients with Type 2 Diabetes
Diabetes Care Publish Ahead of Print, published online November 26, 2007 Factors Affecting Use of Insulin Pens by Patients with Type 2 Diabetes Richard R. Rubin, PhD 1,2 Mark Peyrot, PhD 1,3 1= Department
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationGli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1?
Impatto degli inibitori di SGLT-2 nei pazienti con diabete di tipo 2 Corso SID Hotel Michelangelo, Milano. 26 Giugno 2018 Gli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1? Emanuele
More informationRunning title: Self-monitoring of blood glucose versus urine glucose
Self-monitoring of blood glucose compared to self-monitoring of urine glucose in adults with newly diagnosed Type 2 diabetes receiving structured education: a cluster randomised controlled trial Running
More informationJohn Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPrescription Switching and Reduced LDL-C Goal Attainment
Prescription Switching and Reduced LDL-C Goal Attainment JoAnne M. Foody, MD, FACC, FAHA Brigham and Women's Hospital, Boston, MA Disclosures Consultant for Merck and Pfizer Why Address Adherence? Increasing
More informationABSTRACT. uncontrolled on basal insulin? OADs;
Diabetes Ther (2017) 8:673 682 DOI 10.1007/s13300-017-0252-9 BRIEF REPORT Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal
More informationAs the number of new glucose monitoring devices
DIABETES TECHNOLOGY & THERAPEUTICS Volume 17, Number 9, 2015 ª Mary Ann Liebert, Inc. DOI: 10.1089/dia.2014.0417 ORIGINAL ARTICLE Development of a New Measure for Assessing Glucose Monitoring Device-Related
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationFor patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH
For patients uncontrolled on multiple daily injections of insulin A quick-start guide for your practice Dosing guidance 1,* V-Go: 3 options 1 For initiating V-Go in patients switching from MDI The majority
More informationAdherence with Oral Bisphosphonate Therapy for Osteoporosis Among Patients in Canadian Clinical Practice. Not for Sale or Commercial Distribution
Adherence with Oral Bisphosphonate Therapy for Osteoporosis Among Patients in Canadian Clinical Practice Nader Habib, MD Heather McDonald-Blumer, MD Michele Moss, MBChB, MCFP Angèle Turcotte, MD Copyright
More informationSimilar risk of malignancy with insulin glargine and neutral protamine Hagedorn
Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More information22 Diabetes Care Volume 38, January 2015
22 Diabetes Care Volume 38, January 2015 CLIN CARE/EDUCATION/NUTRITION/PSYCHOSOCIAL Predictors of Nonsevere and Severe Hypoglycemia During Glucose- Lowering Treatment With Insulin Glargine or Standard
More informationDeclaration of interests. Register-based research on safety and effectiveness opportunities and challenges 08/04/2018
Register-based research on safety and effectiveness opportunities and challenges Morten Andersen Department of Drug Design And Pharmacology Declaration of interests Participate(d) in research projects
More informationCase study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease
Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease Authored by Paul Zimmet and Richard Nesto on behalf of the Global Partnership for Effective Diabetes Management.
More informationA Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
More informationBarriers to Achieving A1C Targets: Clinical Inertia and Hypoglycemia. KM Pantalone Endocrinology
Barriers to Achieving A1C Targets: Clinical Inertia and Hypoglycemia KM Pantalone Endocrinology Disclosures Speaker Bureau AstraZeneca, Merck, Novo Nordisk, Sanofi Consultant Novo Nordisk, Eli Lilly, Merck
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
More informationoriginal article Introduction
original article Diabetes, Obesity and Metabolism 17: 1142 1149, 215. 215 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ORIGINAL ARTICLE Glycaemic control and hypoglycaemia
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationGetting Off the Merry-Go-Round Reducing Readmissions for Patients with Diabetes
Getting Off the Merry-Go-Round Reducing Readmissions for Patients with Diabetes Kristi Kulasa, MD Associate Clinical Professor of Medicine Director, Inpatient Glycemic Control University of California
More informationGuidance on the Self-Monitoring of Blood Glucose in Adults with Diabetes
Introduction Guidance on the Self-Monitoring of Blood Glucose in Adults with Diabetes This guideline is designed to offer guidance for primary and secondary care on the use of selfmonitoring of blood glucose
More informationDiabetes Specific Features. Dealing with Diabetes and Depression. Diabetes Nepal Depression. Overview. Depression. Risk factors for Depression
Nepal 13 Dealing with and Overview Prevalence of and Potential Mechanisms Consequences of co-morbidity Clinical Implications Richard IG Holt Professor in and Endocrinology Nepal, Kathmandu 16 February
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated November 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationOriginal Article. Nicholas B. Argento, MD 1 ; Katherine Nakamura, PhD 2 ABSTRACT
Original Article Nicholas B. Argento, MD 1 ; Katherine Nakamura, PhD 2 ABSTRACT Objective: Little information is available on personal real-time continuous glucose monitoring (PCGM) in patients 65 years
More informationSystematically Assessing the Promise of Type 2 Diabetes Remission
Systematically Assessing the Promise of Type 2 Diabetes Remission Is this the Next Frontier of Diabetes Care? Hertzel C. Gerstein MD MSc FRCPC McMaster University & Population Health Research Institute
More informationComparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM
Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM For the first time using CGM to assess glucose control achieved in both groups Richard M. Bergenstal, MD International Diabetes
More informationReal World Evidence: From Efficacy to Effectiveness
Real World Evidence: From Efficacy to Effectiveness Professor Kamlesh Khunti University of Leicester, UK Leicester Diabetes Centre at University Hospitals of Leicester NHS Trust, 2015. Not to be reproduced
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationROLE OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN GLYCEMIC CONTROL AND CARDIOVASCULAR MORTALITY AND MORBIDITY
ROLE OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN GLYCEMIC CONTROL AND CARDIOVASCULAR MORTALITY AND MORBIDITY An Article Review By Dr.Shaikh Khalid Anwar, India (PG Diploma in Diabetes, MMSc in Diabetology Student
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationClinical Practice Guideline Key Points
Clinical Practice Guideline Key Points Clinical Practice Guideline 2008 Key Points Diabetes Mellitus Provided by: Highmark Endocrinology Clinical Quality Improvement Committee In accordance with Highmark
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationPatient adherence to inhaled therapy A clinical perspective. Nicolas Roche Cochin, Site Val de Grâce University Paris Descartes, Paris, France
Patient adherence to inhaled therapy A clinical perspective Nicolas Roche Cochin, Site Val de Grâce University Paris Descartes, Paris, France 1 Disclosures Aerocrine Almirall AstraZeneca Boehringer Ingelheim
More informationT he advent in the 1980s of meters for
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1C Levels in T1D Exchange Clinic
More informationType 2 diabetes is a chronic metabolic
Pill Burden in Patients With Type 2 Diabetes in Germany: Subanalysis From the Prospective, Noninterventional PROVIL Study Matthias Blüher, 1 Ira Kurz, 2 Simone Dannenmaier, 3 and Markus Dworak 3 IN BRIEF
More informationMetformin is the only drug. Sustained release metformin where standard metformin is not tolerated. Julie Brake
Sustained release metformin where standard metformin is not tolerated Julie Brake Article points 1. Few people will continue taking medication while experiencing side effects. 2. Hypoglycaemia does not
More informationABSTRACT BRIEF REPORT
Diabetes Ther (2016) 7:583 590 DOI 10.1007/s13300-016-0179-6 BRIEF REPORT Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationHigh rate of non-adherence to insulin pump: over prescription, overuse or misuse? A population-based case-cohort study.
High rate of non-adherence to insulin pump: over prescription, overuse or misuse? A population-based case-cohort study. Dr. Eugene Merzon MD; Ilia Merhasin, MBA; Dr. Avivit Golan-Cohen MD ; Dr. Shmuel
More informationSUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84
CURRICULUM VITAE RUSSELL D'AMBRA, M.D. July 2014 North Shore Diabetes & Endocrine Associates 3003 New Hyde Park Road Suite 201 New Hyde Park, New York 11042 516-327-0850 EDUCATION: POST-GRADUATE TRAINING:
More informationTABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products
TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationAn estimated 23.6 million people in the United States,
Impact of Treatment Complexity on Adherence and Glycemic Control: An Analysis of Oral Antidiabetic Agents Michael Pollack, MS, Benjamin Chastek, MS, Setareh A. Williams, PhD, and Jane Moran, MD Abstract
More informationImproving Adherence to Chronic Medications: The Physicians Role and How 340b Can Help
Improving Adherence to Chronic Medications: The Physicians Role and How 340b Can Help William Shrank MD MSHS Division of Pharmacoepidemiology & Pharmacoeconomics Harvard Medical School wshrank@partners.org
More informationGetting Hypertension Under Control
Getting Hypertension Under Control Learning Objectives EXPLAIN the factors involved in patient medication non-adherence. OUTLINE the results of studies focusing on medication adherence issues in patients
More informationMACIPA Systematic Case Review Program. A Multidisciplinary Approach to Diabetes Care
MACIPA Systematic Case Review Program A Multidisciplinary Approach to Diabetes Care PURPOSE This collaborative report outlines how Mount Auburn Cambridge Independent Practice Association, Inc. (MACIPA)
More informationIntegrating Behavioral Health into Primary Care: Collaborative-Care Models
Integrating Behavioral Health into Primary Care: Collaborative-Care Models Presented at the National Health Policy Forum September 17 th, 2013 Marc Avery, MD Clinical Associate Professor Associate Director
More informationFlash Glucose Monitoring & Implantable Sensors
Flash Glucose Monitoring & Implantable Sensors Timothy Bailey, MD, FACE, CPI President & CEO, AMCR Institute Clinical Associate Professor, UCSD School of Medicine Disclosures Research Support: Abbott,
More informationPrevention of complications: are we winning or losing the battle. Naveed Sattar Professor of Metabolic Medicine
Prevention of complications: are we winning or losing the battle Naveed Sattar Professor of Metabolic Medicine Duality of Interest Declaration Consultant or speaker for: Amgen, AstraZeneca, Boehringer
More informationTo Take or Not To Take?
To Take or Not To Take? Assessment Question How do the terms adherence & compliance differ? 1. The terms are synonymous 2.Adherence assumes collaboration between patient & provider while compliance suggests
More informationType 2 Diabetes in Practice. An Expert Commentary with Farhad Zangeneh, MD, FACP, FACE A Clinical Context Report
Type 2 Diabetes in Practice An Expert Commentary with Farhad Zangeneh, MD, FACP, FACE A Clinical Context Report Clinical Context: Type 2 Diabetes in Practice Expert Commentary Jointly Sponsored by: and
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationEconomics of Reducing Out-of-Pocket Costs for Cardiovascular Preventive Services for Patients with High Blood Pressure and High Cholesterol
s of Reducing Out-of-Pocket Costs for Cardiovascular Preventive Services for Patients with High Blood Pressure and High Cholesterol Summary Evidence Tables Study Author (Year) Bunting (2008) Prepost Incomplete
More informationPatient and professional accuracy of recalled treatment decisions in out-patient consultations
University of Wollongong Research Online Faculty of Health and Behavioural Sciences - Papers (Archive) Faculty of Science, Medicine and Health 2007 Patient and professional accuracy of recalled treatment
More informationIntervention to improve adherence to Type 2 Diabetes mellitus subjects in rural teaching hospital
Available online at wwwscholarsresearchlibrarycom Scholars Research Library Der Pharmacia Lettre, 2016, 8 (1):361-367 (http://scholarsresearchlibrarycom/archivehtml) ISSN 0975-5071 USA CODEN: DPLEB4 Intervention
More informationEffective Health Care Program
Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is
More informationAnalysis for the Improvement of Inadequate Glycemic Control in Patients with Type 2 Diabetes Mellitus in Nagano, Japan
Shinshu Med J, 66⑸:319~324, 2018 Analysis for the Improvement of Inadequate Glycemic Control in Patients with Type 2 Diabetes Mellitus in Nagano, Japan Ai Sato 1 ), Yoshihiko Sato 1)*, Yuki Kobayashi 1)
More informationREAL-WORLD CHALLENGES IN TYPE 2 DIABETES MELLITUS: WHY A PARADIGM SHIFT IS NEEDED
REAL-WORLD CHALLENGES IN TYPE 2 DIABETES MELLITUS: WHY A PARADIGM SHIFT IS NEEDED This symposium took place on 13 th September 2017 as part of the 53rd Annual Meeting of the European Association for the
More informationTHE COST DRIVERS OF CANCER CARE
THE COST DRIVERS OF CANCER CARE Debra Patt, MD, MPH, MBA David Eagle, MD Ted Okon, MBA Don Sharpe 20156Community Oncology Alliance 1 Welcome & Introductions Debra Patt, MD, MPH, MBA Director of Public
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationThe cost of overweight and obesity in Australia
The cost of overweight and obesity in Australia Stephen Colagiuri, Crystal M Y Lee, Ruth Colagiuri, Dianna Magliano, Jonathan E Shaw, Paul Z Zimmet and Ian D Caterson Australia has one of the highest prevalences
More informationAhrén, Bo; Mathieu, Chantal; Bader, Giovanni; Schweizer, Anja; Foley, James E
Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Ahrén, Bo; Mathieu, Chantal; Bader, Giovanni; Schweizer,
More informationLower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10
6 Diabetes Care Volume 41, January 2018 PERSPECTIVES IN CARE Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10 https://doi.org/10.2337/dc17-1223
More informationPatient adherence to prescribed therapies in type 2 diabetes
n reports n The Economic Rationale for Adherence in the Treatment of Type 2 Diabetes Mellitus Howard Wild, BS Pharm, RPh Patient adherence to prescribed therapies in type 2 diabetes mellitus (T2DM) including
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationSESSION 4 12:30pm 1:45pm
SESSION 4 12:30pm 1:45pm Addressing Renal-Mediated Glucose Homeostasis: Diabetes and the Kidney SPEAKER Davida Kruger, MSN, BC-ADM, APRN Presenter Disclosure Information The following relationships exist
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Continuous or Intermittent Monitoring
More informationCompassionate supply of Antiretrovirals
Characteristics of patients receiving compassionate supply of antiretroviral medications and associated medication costs in a Toronto HIV specialty clinic Deborah Yoong, BScPhm, PharmD. Mark Naccarato,
More information